A multicenter study on the use of purified cannabidiol for children with treatment-resistant developmental and epileptic encephalopathies
Epilepsy & Behavior · 2025
DOI: 10.1016/j.yebeh.2025.110590 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsy & Behavior, 2025. Verfasst von Gabriela Reyes Valenzuela und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hospital de Pediatría Prof. Dr. Juan P Garrahan, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Cannabidiol, Drug Resistant Epilepsy, Anticonvulsants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
OBJECTIVE: This descriptive, real-world, multicenter study aimed to evaluate the efficacy, safety, and tolerability of purified cannabidiol (CBD) as an add-on therapy in children with treatment-resistant developmental and epileptic encephalopathies (DEE). METHODS: Children aged 0.5 to 16 years who met the International League against Epilepsy (ILAE) criteria for drug-resistant DEE and were treated with purified CBD at 10 different centers between March 2021 and December 2024 were included. RESULTS: A total of 551 patients were enrolled. The mean age at CBD initiation was 8.5 years (SD 5 years; range 0.5-18). Median follow-up duration was 22 months (range 13-32). Etiologies were structural in 249 (45 %), genetic in 160 (28.8 %), immune-mediated in five (0.9 %), infectious in three (0.5 %), and unknown in 134 (24.3 %). After 12-32 months of follow-up, 279 patients (50.6 %) had a > 50 % reduction in seizure frequency, including 78 (14.2 %) who became seizure-free. A reduction of 50 % reduction in seizures and 56 (10.2 %) remaining seizure-free. CONCLUSIONS: This study supports the use of purified CBD as an effective, safe, and well-tolerated treatment option for children with drug-resistant DEEs of diverse etiologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital de Pediatría Prof. Dr. Juan P Garrahan, Buenos Aires, Argentina.
- Hospital Público Materno Infantil, Salta, Argentina.
- Hospital del Niño Jesús, Tucuman, Argentina.
- Hospital Pediátrico Humberto H Notti, Mendoza, Argentina.
- Clínica San Lucas, Neuquen, Argentina.
- Hospital de Niños Victor J Vilela, Rosario, Santa Fé, Argentina.
Zitieren
APA
Reyes Valenzuela, G., Espeche, A., Fortini, S., Gamboni, B., Adi, J., Semprino, M., Fasulo, L., Galicchio, S., Cachia, P., Chacón, S., Calvo, A., Beltran, L., Bautista, C., & Caraballo, R. H. (2025). A multicenter study on the use of purified cannabidiol for children with treatment-resistant developmental and epileptic encephalopathies. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2025.110590
Vancouver
Reyes Valenzuela G, Espeche A, Fortini S, Gamboni B, Adi J, Semprino M, et al. A multicenter study on the use of purified cannabidiol for children with treatment-resistant developmental and epileptic encephalopathies. Epilepsy & Behavior. 2025. doi:10.1016/j.yebeh.2025.110590
BibTeX
@article{ReyesValenzuela2025,
author = {Reyes Valenzuela, Gabriela and Espeche, Alberto and Fortini, Sebastian and Gamboni, Beatriz and Adi, Javier and Semprino, Marco and Fasulo, Lorena and Galicchio, Santiago and Cachia, Pedro and Chacón, Santiago and Calvo, Agustin and Beltran, Lucas and Bautista, Claudia and Caraballo, Roberto H},
title = {A multicenter study on the use of purified cannabidiol for children with treatment-resistant developmental and epileptic encephalopathies},
journal = {Epilepsy & Behavior},
year = {2025},
doi = {10.1016/j.yebeh.2025.110590}
}
EUVIMED